SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ABIOMED, Inc. – ‘8-K’ for 8/10/22

On:  Friday, 8/12/22, at 4:05pm ET   ·   For:  8/10/22   ·   Accession #:  950170-22-17121   ·   File #:  1-09585

Previous ‘8-K’:  ‘8-K’ on / for 8/4/22   ·   Latest ‘8-K’:  This Filing

Magnifying glass tilted right emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/12/22  ABIOMED, Inc.                     8-K:5       8/10/22   10:203K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     85K 
 5: R1          Document and Entity Information                     HTML     46K 
 8: XML         IDEA XML File -- Filing Summary                      XML     11K 
 6: XML         XBRL Instance -- abmd-20220810_htm                   XML     15K 
 7: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 3: EX-101.LAB  XBRL Labels -- abmd-20220810_lab                     XML     40K 
 2: EX-101.PRE  XBRL Presentations -- abmd-20220810_pre              XML     33K 
 4: EX-101.SCH  XBRL Schema -- abmd-20220810                         XSD     11K 
 9: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
10: ZIP         XBRL Zipped Folder -- 0000950170-22-017121-xbrl      Zip     18K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:  C:  C: 
  8-K  
 i 0000815094 i false00008150942022-08-102022-08-10

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  i August 10, 2022

 

img17695962_0.jpg 

 i ABIOMED, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 i Delaware

 i 001-09585

 i 04-2743260

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 i 22 Cherry Hill Drive
 i Danvers,  i Massachusetts  i 01923

(Address of Principal Executive Offices, including Zip Code)

( i 978)  i 646-1400

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol

Name of each exchange on which registered

 i Common Stock, $0.01 par value

 i ABMD

 i The NASDAQ Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

 i 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 i 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 i 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 i 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 


 



Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 10, 2022, ABIOMED, Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, shareholders considered and voted on the following proposals, each of which is described in more detail in the Company’s proxy statement filed in connection with the Annual Meeting: (1) the election of Michael R. Minogue, Martin P. Sutter and Paula A. Johnson each as a Class III director to serve a three-year term expiring at the 2025 Annual Meeting of Stockholders; (2) the approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers (as disclosed in the proxy statement filed in connection with the Annual Meeting); and (3) the ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2023.

The holders of 41,944,819 shares of common stock were present or represented by proxy at the Annual Meeting. The results of the votes for each of these proposals were as follows:

Proposal One: Election of Directors

 

Nominee

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

Michael R. Minogue

 

36,742,284

 

2,893,539

 

2,308,996

 

Martin P. Sutter

 

22,443,240

 

17,192,583

 

2,308,996

 

Paula A. Johnson

 

39,091,026

 

544,797

 

2,308,996

 


Proposal Two: Non-Binding, Advisory Vote on Executive Compensation

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

14,295,971

 

25,312,782

 

27,070

 

2,308,996

 


Proposal Three: Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

 

Votes For

 

Votes Against

 

Abstentions

 

Broker Non-Votes

 

41,427,426

 

502,960

 

14,433

 

0

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

 

 

ABIOMED, Inc.

 

 

 

 

 

 

 

 

By:

/s/ Marc A. Began

 

 

 

 

 

Marc A. Began

Executive Vice President, General Counsel and Secretary

Date: August 12, 2022

 

 

 

 

 

 

 



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
3/31/23
Filed on:8/12/224
For Period end:8/10/224,  DEF 14A
 List all Filings 
Top
Filing Submission 0000950170-22-017121   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2022 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Sep. 27, 7:35:34.1pm ET